Latest news with #Duke-NUS
Korea Herald
3 days ago
- Health
- Korea Herald
Duke-NUS celebrates 20 years of medical innovation with largest ever graduating class
SINGAPORE, May 31, 2025 /PRNewswire/ -- Celebrating 20 years of transformative medical education, Duke-NUS Medical School graduated its largest cohort yet today, the Class of 2025, in a vibrant ceremony at the Ngee Ann Kongsi Auditorium in Academia attended by guest-of-honour Mr Ong Ye Kung, Minister for Health. Marking a strategic milestone for Duke-NUS, the graduating class included 72 Doctor of Medicine (MD) graduates—five of whom are also earning PhDs—and 27 PhD candidates from the Integrated Biology and Medicine, Quantitative Biology and Medicine and Clinical and Translational Sciences programmes. Among the MD graduates was the first group of individuals emerging from the Duke-NUS conditional admissions pathways with the National University of Singapore (NUS) and the Singapore University of Technology and Design (SUTD). These pathways are designed to attract talent from engineering, information technology and other undergraduate programmes. Dean Professor Thomas Coffman said: "Collaborating with seven partner universities, including Duke University and NUS, these pathways are designed to allow students to earn a first degree in diverse academic majors while providing an opportunity to seamlessly transition into medicine. It's a powerful model for developing doctors who are outstanding clinicians but also bring valuable multi-disciplinary skills into our healthcare system." This cohort also includes the inaugural batch of graduates of the Master's in Patient Safety and Healthcare Quality (MPSHQ) programme, the first of its kind in Southeast Asia. The MPSHQ is focused on building highly reliable healthcare systems that are of consistent quality and safety. The Class of 2025 represents Duke-NUS' commitment to broadening the skillset and experience of our students, with 41 per cent of MD and MD-PhD graduates having transitioned mid-career from professions that include law, public relations, accounting and mental health peer support. Additionally, 58 per cent of the Class of 2025's graduates are women, underscoring the School's dedication to fostering diversity in the learning environment. Said Dr Faith Wong Pih Yng, previously a modelmaking student and senior peer support specialist at Singapore's Institute of Mental Health, now MD graduate, "Among the many hospital postings, what stood out most vividly was assisting in and witnessing childbirth—the intense anticipation and joy of welcoming a new life into the world was simply unmatched. Ultimately, however, the memories I cherish most are the countless hours spent with my classmates, supporting one another and peer-teaching." Duke-NUS MD graduates received their degrees, awarded jointly by Duke University and the National University of Singapore, in front of friends and family, as well as notable guests, including Duke University School of Medicine Dean Professor Mary Klotman, SingHealth Group CEO Professor Ng Wai Hoe, and keynote speaker, Dr Amy Abernethy, member of Duke University's board of trustees and co-founder of Highlander Health. Caring and compassion underlines the Class of 2025's accomplishments, especially beyond academia. Partaking in a wealth of community service projects, some of their cohort, such as Dr Dana Chow Wai Shin, MD, started the Healthy to Thrive initiative, the first Duke-NUS-led public health screening event dedicated to migrant workers. The cohort was also recognised for their outstanding achievements, which were given out the night before. Awards such as the Singapore Medical Association-Lee Foundation Prizes and Teamsmanship Awards presented to graduates who demonstrated excellence in academics, community service, and leadership. In the aspect of research and scholarship, the Class of 2025 did not flag, publishing an exceptional 253 papers and publications in their time at Duke-NUS, several as first authors in prominent journals such as Nature Medicine, Immunity and EMBO Molecular Medicine. MD-PhD graduate Dr Katherine Nay Yaung, first author on a paper published in Lancet Rheumatology, wrote about artificial intelligence and high-dimensional technologies to diagnose and treat autoimmune diseases, and PhD graduate Dr Aishwarya Prakash, named first author and published in American Heart Association Journal, who found a type of peptide to have protective qualities for the heart after sustaining damage. "The conversations I've had with patients emphasise a shift towards continuity of care and empowering individuals to make their own health choices. In moments where I feel overwhelmed, I remind myself that being a small part of each patient's journey has been a privilege," said Dr Pang Wui Ming Jeremy, recipient of the SingHealth Prize in Family Medicine, Singapore Medical Association-Lee Foundation Teamsmanship Award for exemplary team values in medicine and Duke-NUS Achievement Prize. As Duke-NUS enters its third decade, the School continues to redefine medical education and research, nurturing the next generation of healthcare leaders who are not just exceptional doctors but visionary innovators ready to make an impact in Singapore and beyond. About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
Malaysian Reserve
3 days ago
- Health
- Malaysian Reserve
Duke-NUS celebrates 20 years of medical innovation with largest ever graduating class
Duke-NUS Medical School's Class of 2025 graduates 121 medical and doctoral students, including MDs, MD-PhDs, PhDs, and masters' degrees Landmark first batch of Masters in Patient Safety and Healthcare Quality graduates, unique to Southeast Asia Inaugural graduates from conditional admissions pathways with NUS and SUTD 41% of MD and MD-PhD graduates made bold mid-career shifts from fields such as law, PR, accounting and mental health support SINGAPORE, May 31, 2025 /PRNewswire/ — Celebrating 20 years of transformative medical education, Duke-NUS Medical School graduated its largest cohort yet today, the Class of 2025, in a vibrant ceremony at the Ngee Ann Kongsi Auditorium in Academia attended by guest-of-honour Mr Ong Ye Kung, Minister for Health. Marking a strategic milestone for Duke-NUS, the graduating class included 72 Doctor of Medicine (MD) graduates—five of whom are also earning PhDs—and 27 PhD candidates from the Integrated Biology and Medicine, Quantitative Biology and Medicine and Clinical and Translational Sciences programmes. Among the MD graduates was the first group of individuals emerging from the Duke-NUS conditional admissions pathways with the National University of Singapore (NUS) and the Singapore University of Technology and Design (SUTD). These pathways are designed to attract talent from engineering, information technology and other undergraduate programmes. Dean Professor Thomas Coffman said: 'Collaborating with seven partner universities, including Duke University and NUS, these pathways are designed to allow students to earn a first degree in diverse academic majors while providing an opportunity to seamlessly transition into medicine. It's a powerful model for developing doctors who are outstanding clinicians but also bring valuable multi-disciplinary skills into our healthcare system.' This cohort also includes the inaugural batch of graduates of the Master's in Patient Safety and Healthcare Quality (MPSHQ) programme, the first of its kind in Southeast Asia. The MPSHQ is focused on building highly reliable healthcare systems that are of consistent quality and safety. The Class of 2025 represents Duke-NUS' commitment to broadening the skillset and experience of our students, with 41 per cent of MD and MD-PhD graduates having transitioned mid-career from professions that include law, public relations, accounting and mental health peer support. Additionally, 58 per cent of the Class of 2025's graduates are women, underscoring the School's dedication to fostering diversity in the learning environment. Said Dr Faith Wong Pih Yng, previously a modelmaking student and senior peer support specialist at Singapore's Institute of Mental Health, now MD graduate, 'Among the many hospital postings, what stood out most vividly was assisting in and witnessing childbirth—the intense anticipation and joy of welcoming a new life into the world was simply unmatched. Ultimately, however, the memories I cherish most are the countless hours spent with my classmates, supporting one another and peer-teaching.' Duke-NUS MD graduates received their degrees, awarded jointly by Duke University and the National University of Singapore, in front of friends and family, as well as notable guests, including Duke University School of Medicine Dean Professor Mary Klotman, SingHealth Group CEO Professor Ng Wai Hoe, and keynote speaker, Dr Amy Abernethy, member of Duke University's board of trustees and co-founder of Highlander Health. Caring and compassion underlines the Class of 2025's accomplishments, especially beyond academia. Partaking in a wealth of community service projects, some of their cohort, such as Dr Dana Chow Wai Shin, MD, started the Healthy to Thrive initiative, the first Duke-NUS-led public health screening event dedicated to migrant workers. The cohort was also recognised for their outstanding achievements, which were given out the night before. Awards such as the Singapore Medical Association-Lee Foundation Prizes and Teamsmanship Awards presented to graduates who demonstrated excellence in academics, community service, and leadership. In the aspect of research and scholarship, the Class of 2025 did not flag, publishing an exceptional 253 papers and publications in their time at Duke-NUS, several as first authors in prominent journals such as Nature Medicine, Immunity and EMBO Molecular Medicine. MD-PhD graduate Dr Katherine Nay Yaung, first author on a paper published in Lancet Rheumatology, wrote about artificial intelligence and high-dimensional technologies to diagnose and treat autoimmune diseases, and PhD graduate Dr Aishwarya Prakash, named first author and published in American Heart Association Journal, who found a type of peptide to have protective qualities for the heart after sustaining damage. 'The conversations I've had with patients emphasise a shift towards continuity of care and empowering individuals to make their own health choices. In moments where I feel overwhelmed, I remind myself that being a small part of each patient's journey has been a privilege,' said Dr Pang Wui Ming Jeremy, recipient of the SingHealth Prize in Family Medicine, Singapore Medical Association-Lee Foundation Teamsmanship Award for exemplary team values in medicine and Duke-NUS Achievement Prize. As Duke-NUS enters its third decade, the School continues to redefine medical education and research, nurturing the next generation of healthcare leaders who are not just exceptional doctors but visionary innovators ready to make an impact in Singapore and beyond. About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit
Straits Times
30-04-2025
- Health
- Straits Times
How Duke-NUS Medical School supports staff to drive healthcare innovations
Professor Patrick Tan in his Duke-NUS lab, where groundbreaking cancer genetics research translates into clinical trials with real-world impact. PHOTO: DUKE-NUS MEDICAL SCHOOL BRANDED CONTENT 'Our role is about service': Why staff stay, grow and drive healthcare innovation at this med school Duke-NUS Medical School's culture of open collaboration and access to a vast clinical ecosystem enables its staff to push boundaries in medicine and public health From installing life-saving devices at Housing Board void decks to discovering new cancer treatments, innovation at Duke-NUS Medical School extends beyond the lab. In March 2025, in collaboration with SingHealth, the school launched its Artificial Intelligence in Medicine Institute (AIMI) with the aim to equip healthcare professionals with the tools and support to develop and apply AI solutions in the real world. There is tremendous use for AI, from finding new drugs to understanding complex biological pathways, to detecting patterns in the emergence of diseases, says Professor Patrick Tan, Duke-NUS' senior vice-dean for research. A Stanford-trained MD (Doctor of Medicine)-PhD holder, the 56-year-old was one of the school's pioneer faculty members and has been appointed the next and fourth dean of the school, effective January 1, 2026. 'The character of Duke-NUS is very special,' he says. 'We're a medical school that produces doctors who do more than clinical care, researchers who do more than publish papers, and administrators who lean into our mission of innovative education and impactful research that transforms the practice of medicine in Singapore and beyond.' This sense of shared purpose is echoed by Associate Professor Shiva Sarraf-Yazdi, who sums it up succinctly: 'Our role is about service.' Duke-NUS was established in 2005 as a partnership between two world-class institutions: Duke University and the National University of Singapore. A former Duke-trained surgeon, she joined Duke-NUS more than a decade ago to focus on medical education. 'The act of surgery itself measures impact in days, weeks or months but education measures impact in decades,' says the 53-year-old, who is now the vice-dean for education overseeing the Duke-NUS MD programme. The school has been ranked as one of Singapore's best employers for five years running, in a list compiled by global research firm Statista in collaboration with The Straits Times. Faculty members and staff have cited a high level of trust, strong emphasis on workplace diversity and clear work expectations as factors that make Duke-NUS stand out as an employer. Prof Tan, who leads a 600-strong research office, says: 'Part of my job is to bring in the best people, assemble the best teams, and make sure they can do their best work with supporting structures in place to tackle the big questions of the future.' The setting up of AIMI marks the school's latest move to leverage cutting-edge technology and interdisciplinary expertise to solve complex healthcare challenges and redefine what's possible in patient care. A spirit of innovation at Duke-NUS Medical School empowers every member to push boundaries, to transform medicine and improve lives. (Seated, from left) Professor Patrick Tan, senior vice-dean for research; professor Thomas Coffman, dean; and Dr Zhou Jin, principal research scientist. (Standing, from left) Mr Anirudh Sharma, director, communications and strategic relations; and associate professor Shiva Sarraf-Yazdi, vice-dean for education. PHOTO: DUKE-NUS MEDICAL SCHOOL Creating real-world impact Prof Tan says the scale and success of the work of Duke-NUS researchers is made possible because of the institution's collaborative model and access to Singapore's broader healthcare ecosystem. That includes his own groundbreaking contributions to stomach cancer research. Prof Tan's work in gastric cancer won the American Association for Cancer Research Team Science Award in 2018 – a first for a team from Asia. Supported by Duke-NUS, his team – comprising researchers from the National Cancer Centre Singapore, the Genome Institute of Singapore and collaborators from Japan, Taiwan and Thailand – identified key genetic abnormalities in stomach cancers and translated those findings into targeted clinical trials. Reflecting on his focus on research rather than clinical care, he says: 'When you provide clinical care, it is to one patient at a time. This is tremendously important. But if you can find the cause of disease and therapy to intervene, there is a much broader level of impact.' Another real-world example is the installation of AEDs (Automated External Defibrillators) across Singapore, an initiative led by Duke-NUS' research on out-of-hospital cardiac arrest survival rates. 'It wasn't a drug, but it saved lives. That's the impact,' says Prof Tan. Breakthroughs in medical research and healthcare Fighting cancer From developing Singapore's first home-grown cancer drug (ETC-159) to mapping stomach tumours for personalised therapies, scientists at Duke-NUS are leading advances in cancer treatment. From developing Singapore's first home-grown cancer drug (ETC-159) to mapping stomach tumours for personalised therapies, scientists at Duke-NUS are leading advances in cancer treatment. Pioneering Covid-19 response Duke-NUS is among the first globally to isolate, culture and characterise the SARS-CoV-2 virus, driving innovations in Covid-19 testing, vaccines and therapeutics – including the world's first FDA-approved neutralising antibody test kit. Duke-NUS is among the first globally to isolate, culture and characterise the SARS-CoV-2 virus, driving innovations in Covid-19 testing, vaccines and therapeutics – including the world's first FDA-approved neutralising antibody test kit. Hope for Parkinson's Duke-NUS is advancing cell therapies for brain diseases like Parkinson's, taking these treatments from the lab to clinical trials in Singapore and overseas. Duke-NUS is advancing cell therapies for brain diseases like Parkinson's, taking these treatments from the lab to clinical trials in Singapore and overseas. Driving longevity research Researchers at Duke-NUS discovered how the IL-11 protein is linked to ageing and excess scar tissue build-ups in organs or tissues, paving the way for new treatments. Researchers at Duke-NUS discovered how the IL-11 protein is linked to ageing and excess scar tissue build-ups in organs or tissues, paving the way for new treatments. Beating cardiac arrest Research led to the placement of over 10,000 automated external defibrillators across Singapore and cardiopulmonary resuscitation training for more than 180,000 people annually – dramatically improving survival from cardiac arrests outside hospitals. Empowering bold innovations Prof Sarraf-Yazdi feels the school's innovation-friendly culture encourages bold ideas. This support has enabled her team to embark on new projects that continually enhance the school's education programme to better prepare students for clinical practice. One of her earlier initiatives was the MD Programme Longitudinal Integrated Clerkship. It was run as a pilot to expose students to multiple clinical disciplines in a holistic approach while enabling them to form stronger connections with patients, mentors and peers. Insights from the pilot helped reshape the MD curriculum, such as the longitudinal C.A.R.E. (Connect, Assimilate, Reflect, Explore) Programme, which now spans the entire curriculum. The programme complements students' capabilities for practice by progressively incorporating essential skills like communication, clinical reasoning, ethics and professionalism, while exploring emerging healthcare priority areas such as Population Health and AI in medicine. Associate Professor Shiva Sarraf-Yazdi with Duke-NUS students during one of their clinical education programmes, practising procedural skills in a safe environment. PHOTO: DUKE-NUS MEDICAL SCHOOL 'It is easy to take bold steps when you are backed by a courageous team and supported by institutional leadership that tolerates failure, embraces change and encourages innovation,' she says. In addition to Duke-NUS, she credits the school's extended ecosystem – including over 2,000 clinical faculty across the SingHealth Duke-NUS Academic Medical Centre – for guiding students through their clinical education. Enduring impact on public health At Duke-NUS, professional growth is not limited to students. By providing a supportive environment including flexible work arrangements to encourage lifelong learning, faculty and staff are enabled to deepen their expertise and expand their capabilities. Prof Sarraf-Yazdi herself pursued two additional degrees while working – a Master of Health Professions Education from Johns Hopkins University and a Master of Business Administration from NUS. Programmes such as the Dean's Excellence Awards and Administrative Achievement Awards also help in highlighting staff contributions and fostering peer appreciation. Prof Tan says: 'There is an ethos and culture to Duke-NUS that has sustained me. 'Here, you will find that many of us stay for quite a long time because we're all attracted to this very dynamic place that tackles some of the key and important questions of the future that affect Singapore and the world.' Read more about Singapore's Best Employers 2025. Join ST's WhatsApp Channel and get the latest news and must-reads.
Korea Herald
17-04-2025
- Health
- Korea Herald
Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis
SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that could simplify the analysis of T-cell responses. Point-of-care tests can be performed quickly and easily at the site of patient care, such as in clinics or hospitals, without the need of specialised lab equipment. They provide rapid results, helping doctors and researchers make timely decisions. TCD was established in Singapore in 2021 as a spin-off from Duke-NUS by Professor Antonio Bertoletti, Assistant Professors Nina Le Bert and Anthony Tan from Duke-NUS' Emerging Infectious Diseases Programme. Developed based on the licensed IP and its related know-how, TCD's test kits precisely measure the amount of virus-specific T cells in clinical samples by stimulating biological samples—ranging from whole blood to nasal swabs and bronchoalveolar lavage fluids—with synthetic peptides. In response to the stimulation, the T cells release chemical signals called cytokines, which can be easily measured. Assistant Professor Nina Le Bert, who is currently applying this technology in her research on samples from patients chronically infected with the Hepatitis B Virus, said: "We are impressed by the simplicity and performance of the test kit, which has allowed the testing of hundreds of patient samples with ease and precision. It is heartening to see that the interest in measuring T-cell responses induced by vaccination or infection is gaining traction as such knowledge empowers healthcare providers and researchers to better understand immune responses in patients, in turn driving innovations to improve patient care." Mr Alessandro Sidoli, CEO of T Cell Diagnostics: "We are confident that the addition of this technology to our portfolio is a major step towards achieving our goal of using T cells as a diagnostic. Our team combines deep scientific expertise with a commitment to delivering reliable, high-quality results, ensuring that our partners can confidently advance their research and clinical goals. Whether you're exploring immune responses to viral infections, vaccination, or even cancer, TCD is your trusted partner in unlocking the power of T cell immunity." TCD offers end-to-end solutions, including project management, expert consultations, and advanced research testing services. The main focus is on analysing virus-specific cellular immune responses, with a particular emphasis on infections such as HBV, HDV, Influenza, SARS-CoV-2, and Dengue. By quantifying the number and function of antigen-specific T cells, TCD provides critical insights that can guide diagnosis, treatment, and vaccine development. Operating from a state-of-the-art BSL-2 laboratory in Singapore's Biopolis, TCD is strategically positioned to serve local, regional, and international clients. Associate Professor Christopher Laing, Vice-Dean for Innovation and Entrepreneurship at Duke-NUS, said: "Innovation in science is not just about discovery—it's about turning knowledge into solutions that improve lives. Duke-NUS scientists are among the most entrepreneurial in Asia, and our culture of innovation is supportive of partnering with startups. Our collaboration with TCD exemplifies Duke-NUS' commitment to bridging academia and industry, accelerating groundbreaking discoveries from universities to patients and society." About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
Yahoo
17-04-2025
- Health
- Yahoo
Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis
Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and management of human infectious diseases. SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that could simplify the analysis of T-cell responses. Point-of-care tests can be performed quickly and easily at the site of patient care, such as in clinics or hospitals, without the need of specialised lab equipment. They provide rapid results, helping doctors and researchers make timely decisions. TCD was established in Singapore in 2021 as a spin-off from Duke-NUS by Professor Antonio Bertoletti, Assistant Professors Nina Le Bert and Anthony Tan from Duke-NUS' Emerging Infectious Diseases Programme. Developed based on the licensed IP and its related know-how, TCD's test kits precisely measure the amount of virus-specific T cells in clinical samples by stimulating biological samples—ranging from whole blood to nasal swabs and bronchoalveolar lavage fluids—with synthetic peptides. In response to the stimulation, the T cells release chemical signals called cytokines, which can be easily measured. Assistant Professor Nina Le Bert, who is currently applying this technology in her research on samples from patients chronically infected with the Hepatitis B Virus, said: "We are impressed by the simplicity and performance of the test kit, which has allowed the testing of hundreds of patient samples with ease and precision. It is heartening to see that the interest in measuring T-cell responses induced by vaccination or infection is gaining traction as such knowledge empowers healthcare providers and researchers to better understand immune responses in patients, in turn driving innovations to improve patient care." Mr Alessandro Sidoli, CEO of T Cell Diagnostics: "We are confident that the addition of this technology to our portfolio is a major step towards achieving our goal of using T cells as a diagnostic. Our team combines deep scientific expertise with a commitment to delivering reliable, high-quality results, ensuring that our partners can confidently advance their research and clinical goals. Whether you're exploring immune responses to viral infections, vaccination, or even cancer, TCD is your trusted partner in unlocking the power of T cell immunity." TCD offers end-to-end solutions, including project management, expert consultations, and advanced research testing services. The main focus is on analysing virus-specific cellular immune responses, with a particular emphasis on infections such as HBV, HDV, Influenza, SARS-CoV-2, and Dengue. By quantifying the number and function of antigen-specific T cells, TCD provides critical insights that can guide diagnosis, treatment, and vaccine development. Operating from a state-of-the-art BSL-2 laboratory in Singapore's Biopolis, TCD is strategically positioned to serve local, regional, and international clients. Associate Professor Christopher Laing, Vice-Dean for Innovation and Entrepreneurship at Duke-NUS, said: "Innovation in science is not just about discovery—it's about turning knowledge into solutions that improve lives. Duke-NUS scientists are among the most entrepreneurial in Asia, and our culture of innovation is supportive of partnering with startups. Our collaboration with TCD exemplifies Duke-NUS' commitment to bridging academia and industry, accelerating groundbreaking discoveries from universities to patients and society." About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit View original content to download multimedia: SOURCE Duke-NUS Medical School
